Aloxi palonosetron regulatory update

Helsinn submitted an sNDA to FDA for oral Aloxi palonosetron to treat chemotherapy-induced nausea and vomiting (CINV). MOGN, Helsinn's U.S. marketing partner, markets an injectable formulation of the ...